About Zaiqi Wang

Zaiqi Wang has served as our chairman and CEO since November 2018.Prior to

this, Dr. Zaiqi Wang served as GM, Roche China Innovation Center from 2017 to

Nov 2018 where he managed 140 scientists and over 10 programs from

discovery to early development. From 2011 to 2017, Dr. Zaiqi Wang served as

Vice President at MSD China Development Center during which time he was

responsible for all China clinical programs; key driver for NDA approval of

Keytruda, Gardasil, Zepatir, Rotateq, Noxafil, Emend, Orgalutran and Bridion in

China and led the overall Keytruda China development strategy, especially by

driving melanoma as the leading indication. From 2001 to 2010, Dr. Zaiqi Wang

was served as Director of Early Clinical Research and Experimental Medicine at

Schering Plough where he was responsible for 7 FIH programs, and built up the

translational research unit in Singapore, Chaired VLA-4 early development

program and served as chair for protocol review committee for 2 years.

Previously he was served as Assistant Clinical Pharmacologist, Phase 1 Unit at Eli

Lilly from June 2001 to Dec 2001. Dr. Zaiqi Wang is Internist with board-certified

Clinical Pharmacology in US and he received PhD in Biochemistry from Virginia

Tech and pursued his Postdoc in John Hopkins University.